ARTARA THERAPEUTICS INC TARA 深 滬
已收盤 08-01 16:00:00 美东时间
3.06
-0.040
-1.29%
華盛通- 最 高3.28
- 今 開3.05
- 成交量 30.19万股
- 最 低 3.012
- 昨 收 3.10
- 總市值 1.18亿
- 52周最高 10.48
- 市盈率 靜 --
- 換手率 0.78%
- 52周最低 1.595
- 委 比 96.96%
- 總股本 3858.19万
- 歷史最高 800.00
- 量 比 1.27
- 振 幅 8.65%
- 歷史最低 1.04
- 每 手 1
- 風險率 1.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics granted stock options and RSUs to two new hires, totaling 29,500 options and 14,750 RSUs under its Inducement Plan. The options have an exercise price of $2.80 and vest over four years, while RSUs vest over three years. The company, focused on cancer and rare disease therapies, recently announced these awards to attract and retain key talent, aligned with Nasdaq Listing Rule 5635(c)(4).
07-01 20:12
Protara Therapeutics Announces Addition to the Russell 3000® Index
Protara Therapeutics, Inc. has been added to the Russell 3000® Index, reflecting its progress in advancing therapies for cancer and rare diseases, including clinical trials for TARA-002 and its IV Choline Chloride program. The inclusion enhances the company's visibility among investors.
06-30 12:00
快讯 | Protara Therapeutics 宣布任命威廉·孔克林为首席商务官
Protara Therapeutics Announces Appointment of William Conkling as Chief Commerc...
06-03 04:04
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
Protara Therapeutics appointed William “Bill” Conkling as Chief Commercial Officer, bringing over two decades of experience in developing and commercializing cancer and rare disease therapies. Conkling previously led the successful launch of Trodelvy at Immunomedics and managed Kymriah at Novartis. Jesse Shefferman, CEO of Protara, highlighted Conkling’s expertise in building commercial organizations and expressed confidence in the company’s tran...
06-02 20:04
美股大行评级 | 高盛上调微软目标价从480美元至550美元，Snowflake获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132593314765758464.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持IDEAYA Biosciences(IDYA)"超配"评级，目标价从63美元升至66美元</p> <p>• Needham：上调Inogen(INGN)评级至"买入"，目标价12美元</p> <p>• E
05-23 11:19
Jones Trading Initiates Coverage On Protara Therapeutics with Buy Rating, Announces Price Target of $21
Jones Trading analyst Soumit Roy initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Buy rating and announces Price Target of $21.
05-22 23:04
Protara Therapeutics Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-22 23:03
Protara Therapeutics Q1 EPS $(0.29) Beats $(0.45) Estimate
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.45) by 35.56 percent. This is a 70.1 percent increase over losses of $(0.97) per share
05-08 20:08
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: ...
05-02 04:09
快讯 | Protara Therapeutics公司根据纳斯达克上市规则5635(C)(4)报告诱因授予。
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule ...
05-02 04:09
